Allergy & ImmunologyCendakimabEosinophilic Esophagitis
IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management
By MedXY|Dec 31, 2025
A Phase 3 trial demonstrates that cendakimab significantly reduces dysphagia days and improves histologic and endoscopic markers in patients with eosinophilic esophagitis, offering a targeted therapeutic approach for this chronic type 2 inf
